Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27231741 | 0.84 | KDM4E (0.72) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL27918053 | 0.84 | KDM4E (0.62) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL29483170 | 0.83 | KDM4E (0.47) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| Benzene SCHEMBL11818131 | 0.82 | KDM4E (0.70) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL990359 | 0.82 | KDM4E (0.70) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL353589 | 0.82 | KDM4E (0.70) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL10567722 | 0.82 | KDM4E (0.60) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL8710514 | 0.81 | KDM4E (0.68) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL131588 | 0.81 | KDM4E (0.68) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL1060005 | 0.81 | KDM4E (1.00) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884095-B | Macrocyclic ligands with picolinate groups, complexes thereof and medical uses thereof | 法国加柏公司 | 2021-07-16 | — | — | CN | disclosed |
| US-10981912-B2 | Macrocyclic ligands with picolinate group(s), complexes thereof and also medical uses thereof | GUERBET (FR) | 2021-04-20 | — | — | US | disclosed |
| US-10711001-B2 | Macrocylic ligands with picolinate group(s), complexes thereof and also medical uses thereof | GUERBET (FR) | 2020-07-14 | — | — | US | disclosed |
| US-20200123155-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2020-04-23 | — | — | US | disclosed |
| US-20190023705-A1 | MACROCYLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-01-24 | — | — | US | disclosed |
| EP-3394063-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF | Guerbet (FR) | 2018-10-31 | — | — | EP | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2014059185-A1 | AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-2350051-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2342188-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010056549-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023705-A1 | MACROCYLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF | PPIG, GRPR, FKBP3 | KDM4E 4169/4885MAPT 1696/4885CYP1A2 3148/4885 |
| US-10711001-B2 | Macrocylic ligands with picolinate group(s), complexes thereof and also medical uses thereof | PPIG, GRPR, FKBP3 | KDM4E 4169/4885MAPT 1696/4885CYP1A2 3148/4885 |
| US-10981912-B2 | Macrocyclic ligands with picolinate group(s), complexes thereof and also medical uses thereof | PYGL, PPIG, PPIB | KDM4E 4720/4885MAPT 2350/4885CYP1A2 658/4885 |
| US-20200123155-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF | PYGL, PPIG, PPIB | KDM4E 4720/4885MAPT 2350/4885CYP1A2 658/4885 |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 3126/4885MAPT 257/4885CYP1A2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.